 | | DRUG: Perphenazine | |
| Entry |
|
|---|
| Name |
Perphenazine (JP18/USP/INN);
Trilafon (TN) |
|---|
| Product |
|
|---|
| Generic |
PERPHENAZINE (Actavis Pharma), PERPHENAZINE (American Health Packaging), PERPHENAZINE (Bryant Ranch Prepack), PERPHENAZINE (Bryant Ranch Prepack), PERPHENAZINE (Bryant Ranch Prepack), PERPHENAZINE (Bryant Ranch Prepack), PERPHENAZINE (Bryant Ranch Prepack), PERPHENAZINE (Bryant Ranch Prepack), PERPHENAZINE (Bryant Ranch Prepack), PERPHENAZINE (Bryant Ranch Prepack), PERPHENAZINE (Bryant Ranch Prepack), PERPHENAZINE (Chartwell RX), PERPHENAZINE (GOLDEN STATE MEDICAL SUPPLY), PERPHENAZINE (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals), PERPHENAZINE (Major Pharmaceuticals), PERPHENAZINE (Par Pharmaceutical), PERPHENAZINE (Proficient Rx LP), PERPHENAZINE (REMEDYREPACK), PERPHENAZINE (REMEDYREPACK), PERPHENAZINE (REMEDYREPACK), PERPHENAZINE (REMEDYREPACK), PERPHENAZINE (REMEDYREPACK), PERPHENAZINE (REMEDYREPACK), PERPHENAZINE (REMEDYREPACK), PERPHENAZINE (REMEDYREPACK), PERPHENAZINE (REMEDYREPACK), PERPHENAZINE (REMEDYREPACK), PERPHENAZINE (REMEDYREPACK), PERPHENAZINE (Rising Pharmaceuticals), PERPHENAZINE (Sandoz), PERPHENAZINE (Wilshire Pharmaceuticals), PERPHENAZINE (Zydus Lifesciences Limited), PERPHENAZINE (Zydus Pharmaceuticals (USA)) |
|---|
| Formula |
C21H26ClN3OS
|
|---|
| Exact mass |
403.1485
|
|---|
| Mol weight |
403.9686
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Neuropsychiatric agent
DG01478 Dopamine antagonist
DG01474 Dopamine D2-receptor antagonist
DG03200 Antipsychotic agent
DG01905 Phenothiazine antipsychotics
Metabolizing enzyme substrate
DG01644 CYP2D6 substrate
|
|---|
| Remark |
| Therapeutic category: | 1172 |
| Product (DG00875): | D00503<JP/US> D02037<JP> D04038<JP> D04965<JP> |
| Product (mixture): | D10294<US> |
|
|---|
| Efficacy |
Antipsychotic, Dopamine D2 receptor antagonist |
|---|
| Disease |
|
|---|
| Comment |
Phenothiazine derivative
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04080 | Neuroactive ligand-receptor interaction |
|
|---|
| Metabolism |
Enzyme: CYP2D6 [HSA: 1565]
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07029 | Antipsychotics - phenothiazines |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N05 PSYCHOLEPTICS
N05A ANTIPSYCHOTICS
N05AB Phenothiazines with piperazine structure
N05AB03 Perphenazine
D00503 Perphenazine (JP18/USP/INN) <JP/US>
USP drug classification [BR:br08302]
Antiemetics
Antiemetics, Other
Perphenazine
D00503 Perphenazine (JP18/USP/INN)
Antipsychotics
1st Generation/Typical
Perphenazine
D00503 Perphenazine (JP18/USP/INN)
Therapeutic category of drugs in Japan [BR:br08301]
1 Agents affecting nervous system and sensory organs
11 Agents affecting central nervous system
117 Psychotropics
1172 Phenothiazines
D00503 Perphenazine (JP18/USP/INN)
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01478 Dopamine antagonist
DG01474 Dopamine D2-receptor antagonist
DG00875 Perphenazine
D00503 Perphenazine
DG03200 Antipsychotic agent
DG01905 Phenothiazine antipsychotics
DG00875 Perphenazine
D00503 Perphenazine
Metabolizing enzyme substrate
DG01644 CYP2D6 substrate
DG00875 Perphenazine
D00503 Perphenazine
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Dopamine
DRD2
D00503 Perphenazine (JP18/USP/INN) <JP/US>
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
D00503 Perphenazine
D00503 Perphenazine tablets
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D00503
Pharmacogenomic biomarkers [br08341.html]
Polymorphisms and mutations affecting drug response
D00503
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01478 Dopamine antagonist
DG01474 Dopamine D2-receptor antagonist
DG00875 Perphenazine
DG03200 Antipsychotic agent
DG01905 Phenothiazine antipsychotics
DG00875 Perphenazine
Metabolizing enzyme substrate
DG01644 CYP2D6 substrate
DG00875 Perphenazine
|
|---|
| Other DBs |
|
|---|
| KCF data |
ATOM 27
1 C8x C 16.1000 -11.4100
2 C8x C 16.1000 -12.8100
3 C8x C 17.3124 -13.5100
4 C8y C 18.5249 -12.8100
5 C8y C 18.5249 -11.4100
6 C8x C 17.3124 -10.7100
7 S2x S 19.7373 -13.5100
8 C8y C 20.9497 -12.8100
9 C8y C 20.9497 -11.4100
10 N4y N 19.7373 -10.7100
11 C8x C 22.1622 -13.5100
12 C8x C 23.3746 -12.8100
13 C8y C 23.3746 -11.4100
14 C8x C 22.1622 -10.7100
15 C1b C 19.7373 -9.3100
16 C1b C 20.9518 -8.6088
17 C1b C 22.1483 -9.2998
18 N1y N 23.3351 -8.6146
19 C1x C 24.5266 -9.3028
20 C1x C 25.7391 -8.6029
21 N1y N 25.7393 -7.2029
22 C1x C 24.5478 -6.5148
23 C1x C 23.3353 -7.2146
24 C1b C 26.9641 -6.4958
25 C1b C 28.1720 -7.1932
26 O1a O 29.3532 -6.5113
27 X Cl 24.5911 -10.7077
BOND 30
1 1 2 2
2 2 3 1
3 3 4 2
4 4 5 1
5 5 6 2
6 1 6 1
7 4 7 1
8 7 8 1
9 8 9 1
10 9 10 1
11 5 10 1
12 8 11 2
13 11 12 1
14 12 13 2
15 13 14 1
16 9 14 2
17 10 15 1
18 15 16 1
19 16 17 1
20 17 18 1
21 18 19 1
22 19 20 1
23 20 21 1
24 21 22 1
25 22 23 1
26 18 23 1
27 21 24 1
28 24 25 1
29 25 26 1
30 13 27 1
|
|---|
|
» Japanese version » Back
|
|